论文部分内容阅读
目的探讨多西他赛序贯香菇多糖治疗非小细胞肺癌(NSCLC)胸腔积液的疗效与安全性。方法将46例诊断明确NSCLC恶性胸腔积液患者随机分为观察组和对照组,每组23例。观察组排尽胸水后先后胸腔注入多西他赛和香菇多糖,对照组排尽胸水后胸腔注入多西他赛治疗。结果两组胸腔积液均有不同程度的缓解,观察组总有效率86.96%,对照组总有效率60.87%,观察组疗效明显优于对照组(P<0.05)。两组未发生置管穿刺、抽液治疗的相关不良反应,未出现明显肝、肾功能损害和心脏损害。观察组和对照组均有骨髓抑制(7例、9例)、恶心呕吐(6例、6例)、胸痛(4例、6例)、发热(5例、3例)发生,经对症处理后好转,两组不良反应发生率相当(P>0.05)。结论多西他赛序贯香菇多糖治疗恶性胸腔积液疗效确切,毒副反应小。
Objective To investigate the efficacy and safety of docetaxel sequential lentinan in the treatment of non-small cell lung cancer (NSCLC) pleural effusion. Methods 46 cases of NSCLC with malignant pleural effusion were randomly divided into observation group and control group, with 23 cases in each group. In the observation group, docetaxel and lentinan were injected into the pleural cavity after the pleural effusion had been drained, and the control group was treated with docetaxel after pleural effusion. Results The pleural effusion in both groups was relieved to varying degrees. The total effective rate was 86.96% in the observation group and 60.87% in the control group. The observation group was significantly better than the control group (P <0.05). The two groups did not take catheter puncture, pump-related adverse reactions, no significant hepatic and renal dysfunction and heart damage. Myelosuppression (7 cases, 9 cases), nausea and vomiting (6 cases, 6 cases), chest pain (4 cases, 6 cases) and fever (5 cases, 3 cases) occurred in the observation group and the control group. After symptomatic treatment Improvement, the incidence of adverse reactions in both groups (P> 0.05). Conclusion Docetaxel sequential mushroom lectin treatment of malignant pleural effusion, the exact side effects.